Direct immunofluorescence (DIF) microscopy showed a 15.5% positivity rate in pediatric patients and changed the clinical diagnosis in 16.7% of those cases. Researchers conducted a retrospective ...

A man in his 70s with a history of unresectable hepatocellular carcinoma (HCC) treated with nivolumab presented with a blistering rash 14 months after nivolumab initiation. Biopsies and direct ...

Bullous pemphigoid is a rare and severe adverse reaction to immune-checkpoint inhibitors that can be life-threatening. Here, we present two cases of bullous pemphigoid secondary to nivolumab and ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

The FDA has approved Sanofi and Regeneron’s Dupixent as a treatment for adults with bullous pemphigoid, a rare chronic autoimmune skin condition that causes severe itching, painful blisters and open ...

Dupilumab for bullous pemphigoid induced by immune checkpoint inhibitors. Stephen W. Dusza , Gopa Iyer , Alina Markova Journal of Clinical Oncology 2025 43: 16_suppl , e24110-e24110 View Options ...